Form 4: Apellis CTO Sells Shares for Tax Withholding

Apellis Pharmaceuticals' Chief Technical Officer, Nur Nicholson, sold 2,203 shares of common stock to cover tax obligations related to RSU vesting.

Summary

• Nur Nicholson, Chief Technical Officer of Apellis Pharmaceuticals, Inc. (APLS), reported a transaction on January 20, 2026.
• The transaction involved the sale of 2,203 shares of Apellis Pharmaceuticals Common Stock.
• The shares were sold at a price of $19.7929 per share.
• The total value of the shares sold was approximately $43,600.00.
• This sale was conducted to cover tax withholding obligations arising from the release of Restricted Stock Units (RSUs) on January 16, 2026.
• Following this transaction, Nur Nicholson beneficially owns 78,843 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this Form 4 reports a routine, non-discretionary sale of shares to cover tax withholding obligations related to RSU vesting, which is a common occurrence for executives and does not typically reflect a change in management's confidence or the company's fundamentals.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction for tax purposes and does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine tax-related sale and not a discretionary divestment, unlikely to signal a change in company prospects.

Key Dates

Keywords

Apellis Pharmaceuticals, APLS, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Nur Nicholson, Chief Technical Officer